证券代码：600165 股票简称：*ST 宁科 公告编号：临 2025-054 宁夏中科生物科技股份有限公司 关于再次延期回复上海证券交易所对公司 2024 年 年度报告的信息披露监管问询函的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁夏中科生物科技股份有限公司（以下简称：公司）于 2025 年 3 月 31 日收 到上海证券交易所（以下简称：上交所）下发的《关于宁夏中科生物科技股份有 限公司 2024 年年度报告的信息披露监管问询函》（上证公函【2025】0318 号） （以下简称：《年报问询函》），并要求公司在 10 个交易日内进行书面回复并履行 信息披露义务。具体内容详见公司于 2025 年 4 月 1 日披露的《收到<关于宁夏中 科生物科技股份有限公司 2024 年年度报告的信息披露监管问询函>的公告》（公 告编号：临 2025-047）。 公司收到《年报问询函》后高度重视，积极组织各方对所涉及的相关问题进 行逐项回复。鉴于《年报问询函》需回复的部分问题涉及的数据量较大，部分内 容需要进一步补充和完善，因此 ...

Core Viewpoint - The new delisting regulations in A-shares are intensifying, leading to an accelerated "survival of the fittest" process in the market, with a recent surge in delisting risk warnings from multiple companies [1] Group 1: Companies at Risk - ST Xintong is facing delisting risk due to 368 million yuan in non-operating fund occupation, with a two-month deadline for rectification [2] - ST Ningke is projected to incur a loss of 580 to 650 million yuan in 2024, with non-deductible revenue below 300 million yuan, risking delisting if the annual report receives an "unable to express opinion" audit [5][6] - ST Dayao has seen its market value drop below 500 million yuan, making it the first trading delisting stock of 2025, with a stock price plummeting to 1.18 yuan [7][8] - ST Modern has not completed regulatory rectification on time and risks delisting if it fails to submit an audit proof within two months [9][10] Group 2: Regulatory Background - The 2025 delisting regulations have tightened financial indicators, including continuous losses, revenue below 300 million yuan with negative net assets, and excessively low market value [11] - Regulatory scrutiny on information disclosure violations and financial fraud has intensified, exemplified by the case of Dongfang Group, which inflated revenue by 16.1 billion yuan over four years [11] Group 3: Investor Guidance - Investors are advised to avoid high-risk stocks, particularly ST and *ST stocks, companies with continuous losses, and those with abnormal stock price fluctuations [12] - Caution is advised against "doomsday speculation," as some ST stocks may experience short-term surges followed by sharp declines due to major shareholders offloading [13] - Investors should focus on the quality of financial reports, particularly looking for non-standard audit opinions and issues related to major shareholder fund occupation [14] - A rational perspective on "shell protection" expectations is necessary, as the accelerated delisting process under new regulations poses high risks for speculative bottom-fishing [15]

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global technological revolution, providing innovative solutions to major challenges such as health, climate change, and food security, as highlighted by the National Development and Reform Commission's "14th Five-Year Plan for Bioeconomic Development" [4] - The Huazhong Securities synthetic biology index, which includes 58 companies across various sectors, has seen a decline of 9.66% recently, underperforming compared to the Shanghai Composite Index [5][17] Industry Market Dynamics - The synthetic biology sector's stocks have performed poorly recently, with a 9.66% drop, ranking 32nd among sectors [17] - The top five gainers in the synthetic biology sector include: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxiang Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The top five losers include: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yabao Chemical (-9%) - Berry Genomics (-7%) - Weilan Bio (-6%) [22] Company Business Developments - Anhui Pucan has launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate its polyurethane supply chain, with projected revenues exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] - Kosemet announced a partnership with Shanghai Xinhai Biotechnology to develop bio-synthesized retinol for skincare products [25] Industry Financing Tracking - The synthetic biology sector has seen accelerated financing, with nearly 100 companies completing new funding rounds since the beginning of 2025 [28] - Zhongsheng Suyuan Biotechnology completed a B round financing of 235 million yuan, focusing on iPSC-derived cell therapies [28] - Korean company INTAKE raised approximately 9.2 million USD in a C round financing to develop precision fermentation proteins [29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom protein received FDA GRAS certification, allowing it to enter the U.S. market [31] - MycoTechnology's truffle sweet protein product received FEMA GRAS certification, showcasing advancements in natural flavoring solutions [32] - Nourish Ingredients and Cabio Biotech successfully commercialized a precision fermentation fat product, enhancing the flavor of plant-based products [34]

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global revolution, integrating into economic and social development to address major challenges such as health, climate change, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Bioeconomic Development," indicating a trillion-yuan market potential in the bioeconomy [4] Industry Market Dynamics - The synthetic biology index decreased by 9.66% to 1437.31 during the week of April 5-11, 2025, underperforming compared to the Shanghai Composite Index, which fell by 1.62%, and the ChiNext Index, which dropped by 4.21% [5][17] - The top five performing companies in the synthetic biology sector during this period were: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxing Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The bottom five performing companies were: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yaborn Chemical (-9%) - Berry Genomics (-7%) - Blue Biological (-6%) [22] Company Business Developments - Anhui Pucan launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate the polyurethane supply chain, with projected combined revenue exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] Industry Financing Tracking - Synthetic biology companies are accelerating financing, with nearly 100 firms completing new rounds of funding since the beginning of 2025. Zhongsheng Suyuan Biotechnology raised 235 million yuan in its B round, focusing on iPSC-derived cell therapies [28][29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom mycelium protein received FDA GRAS certification, allowing entry into the U.S. market [31] - MycoTechnology's truffle sweet protein ClearHT received FEMA GRAS certification, showcasing advancements in natural flavoring and health foods [32]

证券代码：600165 股票简称：*ST 宁科 公告编号：临 2025-052 宁夏中科生物科技股份有限公司 关于召开 2024 年度网上业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 4 月 18 日（星期五）15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 报 中 国 证 券 网 路 演 中 心 （ 网 址 ： http://roadshow.cnstock.com/） 会议召开方式：网络互动 投资者可于 2025 年 4 月 14 日（星期一）17:00 前将相关问题通过电子邮 件的形式发送至宁夏中科生物科技股份有限公司（以下简称：公司）邮箱： official@ningkeshengwu.com。公司将在信息披露允许范围内，在 2024 年度网上 业绩说明会对投资者普遍关注的问题进行回答。 公司已于 2025 年 3 月 15 日发布公司 2024 年年度报告，为便于广大投资者 更全面深入地了解公司 2024 年度经营成果、财务状况，公司计 ...

证券代码：600165 股票简称：*ST 宁科 公告编号：临 2025-051 宁夏中科生物科技股份有限公司 关于重大诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容及风险提示： ● 截至本公告披露日，宁夏中科生物科技股份有限公司（以下简称：公司） 整体债务规模为 19.27 亿元、其中逾期债务总规模为 17.28 亿元，涉诉债务规 模为 18.30 亿元，除子公司宁夏华辉环保科技股份有限公司（以下简称：华辉 环保）及其全资子公司宁夏天福活性炭有限公司（以下简称：宁夏天福）的银 行账户外，公司及宁夏新日恒力国际贸易有限公司（以下简称：恒力国贸）大 部分银行账户被冻结。虽中科新材银行账户已全部解冻，但公司目前严重缺乏 用于偿债的资金和流动资产，结合目前债务风险巨大的情况，公司持续经营能 力面临严重的负面影响，不能清偿到期债务且明显缺乏清偿能力，具备破产原 因。 ● 案件所处的诉讼阶段：一审判决。 ● 上市公司所处的当事人地位：被告 ● 涉案的金额：贷款本金及利息合计 578,537,158.34 元，自 ...

关 于 宁 夏 中 科 生 物 科 技 股 份 有 限 公 司 2024 年 年 度 股 东 大 会 法 律 意 见 书 北 京 大 成 （ 银 川 ） 律 师 事 务 所 www.dentons.cn 银川市金凤区宁安大街 64 号德丰大厦 25 层（750011） 25/F, Defeng Skyscraper, No.64 Ning'an Street, Jinfeng District, 750011, Yinchuan, China Tel: +86 951-5057676 Fax: +86 951-5057863 关于宁夏中科生物科技股份有限公司 2024 年年度股东大会法律意见书 大成（银）证字[2025]第 G002 号 关于宁夏中科生物科技股份有限公司 2024 年年度股东大会法律意见书 大成（银）证字[2025]第 G002 号 致：宁夏中科生物科技股份有限公司 北京大成（银川）律师事务所受宁夏中科生物科技股份有限公司（以下简称 "公司"）的委托，就公司召开2024年年度股东大会（以下简称"本次股东大会"） 的有关事宜，指派本所马媛、郑亚楠律师（以下简称"本所律师"）出席本次股 东大会，并 ...

证券代码：600165 证券简称：*ST 宁科 公告编号：2025-050 宁夏中科生物科技股份有限公司 2024 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 340 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 235,591,363 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总 | 34.40 | | 数的比例（%） | | 二、 议案审议情况 (一) 非累积投票议案 重要内容提示： 1 (一) 股东大会召开的时间：2025 年 4 月 7 日 (二) 股东大会召开的地点：宁夏中科生物科技股份有限公司（以下简称：公 司）会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会的召集人是公司董事会，表决方式符合《中华人民共和国公司 法》 ...

Core Viewpoint - Ningxia Zhongke Biotechnology Co., Ltd. (*ST Ningke*) and its actual controller, Yu Jianming, received administrative penalties from the China Securities Regulatory Commission (CSRC) for violations related to information disclosure and financial reporting [1][2][10]. Group 1: Administrative Penalties - The CSRC issued two "Notice of Administrative Penalty" letters to *ST Ningke* and Yu Jianming on October 30, 2024, for suspected violations of information disclosure laws [1][2]. - On April 3, 2025, the CSRC confirmed the administrative penalties, which included a warning and fines totaling 5.5 million yuan for *ST Ningke* and various fines for responsible individuals [20][21][22]. Group 2: Violations Identified - *ST Ningke* was found to have inflated its 2022 revenue by 76.5941 million yuan and profit by 77.222 million yuan, constituting 11.25% and 46.59% of the reported figures, respectively [10]. - The company failed to timely disclose significant debts totaling 108 million yuan and the suspension of its subsidiary's operations, which were deemed major events under securities law [13][14]. Group 3: Responsible Individuals - Yu Jianming, as the actual controller, was found to have organized and directed the financial misreporting, leading to severe penalties [10][21]. - Other key individuals, including Huang Haisu (Chairman), Chen Rui (General Manager), and Dong Chunxiang (CFO), were also held accountable for their roles in the violations [11][14][20]. Group 4: Company Response and Future Actions - Following the penalties, *ST Ningke* has committed to improving compliance and internal controls to prevent future violations, emphasizing the importance of accurate and timely information disclosure [25][30]. - The company has expressed regret over the incident and is taking steps to enhance the understanding of relevant laws and regulations among its personnel [25][30].